The Operational Group is chaired by the Project Coordinator (Serena Scollen). It will bring together WP leaders and 1+MG Working Group (WG) leaders to monitor the project progress. It will report and make recommendations to the Governing Board on decisions that have a significant impact for the B1MG project. For non-significant decisions the Group will be the decision body. Minutes of the monthly meetings are distributed to the Board and the General Assembly, and when feasible the Group's meetings are co-located with 1+MG Coordination Team meetings.
B1MG participants
|
Serena Scollen (ELIXIR Hub) |
Project Coordinator |
Denis Horgan (EAPM), Ruben Kok (DTL-Projects), Jan Korbel (EMBL Heidelberg), Toni Andreu (EATRIS) |
WP1 |
Regina Becker (UNILU), Jasper Boveberg (Legal Pathways) |
WP2 |
Ivo Gut (CRG), Jeroen Belien (VUmc) |
WP3 |
Tommi Nyrönen (CSC), Ilkka Lappalainen (CSC), Bengt Persson (UU), Sergei Beltran (CRG) |
WP4 |
Astrid Vincente (CSC), Serena Scollen (ELIXIR Hub) |
WP5 |
Juan Arenas (ELIXIR Hub), Esther Rodriguez (ISCIII) |
WP6 |
1+MG participants
|
Fernando Martin Sanchez (ISCIII) |
1+MG WG1 Scope, stakeholders, organisation and governance |
Regina Becker (UNILU) |
1+MG WG2 Ethical, Legal, and Social Issues (ELSI) |
Jeroen Belien (VUmc) |
1+MG WG3 Common standards and minimal dataset for clinical and phenotypic data |
Ivo Gut( CRG) |
1+MG WG4 Good sequencing practice |
Tommi Nyrönen (CSC) |
1+MG WG5 Federated, secure, interoperable and privacy-respecting framework and access governance |
Iñaki Imaz Iglesias (ISCIII) |
1+MG WG6 Health economics and outcome research |
TBD |
1+MG WG7 Use case: Involvement of the private sector |
Marco Tartaglia (OPBG), Olaf Riess (TbU) |
1+MG WG8 Use case: Rare diseases |
Giovanni Tonno (HSR) |
1+MG WG9 Use case: Cancer |
Andres Metspalu (UT) |
1+MG WG10 Use case: Common and complex diseases, incl. pharmacogenomics |
Andreas Scherer (Helsinki) |
1+MG WG11 Use case: Infectious diseases |
André Uitterlinden (Erasmus MC) |
1+MG WG12 Use case: Population Genomics |